Intranasal insulin directly elevates brain insulin and significantly ameliorates the cognitive impairment in T2D patients (Gaddam et al. 2021), suggesting that enhancing the brain insulin is feasible in treatment of AD. This evidence concerns the gene INS and type 2 diabetes mellitus.